Naltrexone / bupropion (Mysimba®)
Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.
| NCPE Assessment Process | Complete |
| Rapid review received | 12/03/2017 |
| Rapid review completed | 28/03/2017 |
| Rapid Review outcome | A Full pharmacoeconomic assessment is recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 29/03/2017 |
| Pre-submission consultation with applicant | 29/05/2017 |
| Submission received from applicant | 06/11/2017 |
| Preliminary review sent to applicant | 05/01/2018 |
| NCPE assessment re-commenced | 01/02/2018 |
| Factual accuracy sent to applicant | 24/04/2018 |
| NCPE assessment re-commenced | 01/05/2018 |
| NCPE assessment completed | 09/05/2018 |
| Full pharmacoeconomic assessment outcome | The NCPE recommends that naltrexone/bupropion (Mysimba ®) should not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |